Cargando…

The Clinical Efficacy of Fibrinogen Concentrate in Massive Obstetric Haemorrhage with Hypofibrinogenaemia

Massive obstetric haemorrhage remains a major cause of maternal death attributable to hypofibrinogenaemia. Transfusion of large volumes of fresh frozen plasma (FFP) is required to normalise fibrinogen levels. We compared the efficacy of FFP (F group) with that of FFP plus fibrinogen concentrate (F +...

Descripción completa

Detalles Bibliográficos
Autores principales: Matsunaga, Shigetaka, Takai, Yasushi, Nakamura, Eishin, Era, Sumiko, Ono, Yoshihisa, Yamamoto, Koji, Maeda, Hiroo, Seki, Hiroyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5402272/
https://www.ncbi.nlm.nih.gov/pubmed/28436465
http://dx.doi.org/10.1038/srep46749
_version_ 1783231195532754944
author Matsunaga, Shigetaka
Takai, Yasushi
Nakamura, Eishin
Era, Sumiko
Ono, Yoshihisa
Yamamoto, Koji
Maeda, Hiroo
Seki, Hiroyuki
author_facet Matsunaga, Shigetaka
Takai, Yasushi
Nakamura, Eishin
Era, Sumiko
Ono, Yoshihisa
Yamamoto, Koji
Maeda, Hiroo
Seki, Hiroyuki
author_sort Matsunaga, Shigetaka
collection PubMed
description Massive obstetric haemorrhage remains a major cause of maternal death attributable to hypofibrinogenaemia. Transfusion of large volumes of fresh frozen plasma (FFP) is required to normalise fibrinogen levels. We compared the efficacy of FFP (F group) with that of FFP plus fibrinogen concentrate (F + F group) in massive obstetric haemorrhage. In this retrospective study, we compared the medical charts (2004–2016) of 137 patients with <150 mg/dl fibrinogen treated with F + F (n = 47; after August 2009) or F (n = 56; before August 2009). Although fibrinogen concentrate was only administered in severe cases, the FFP/red blood cell concentrate (RCC) ratio was significantly lower in the F + F group than in the F group. A sub-group analysis of cases requiring ≥18 RCC units showed that the F + F group received significantly less FFP than the F group (40.2 ± 19.6 versus 53.4 ± 18.5 units; P = 0.047) and showed significantly less pulmonary oedema (24.0% vs 57.1%; P < 0.05) in the absence of any significant differences in pre-transfusion coagulation, estimated blood loss, or RCC transfusion volume. Administration of fibrinogen concentrate increased the rate of fibrinogen supplementation five-fold and reduced FFP dosage, the FFP/RCC ratio, and the incidence of pulmonary oedema.
format Online
Article
Text
id pubmed-5402272
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-54022722017-04-26 The Clinical Efficacy of Fibrinogen Concentrate in Massive Obstetric Haemorrhage with Hypofibrinogenaemia Matsunaga, Shigetaka Takai, Yasushi Nakamura, Eishin Era, Sumiko Ono, Yoshihisa Yamamoto, Koji Maeda, Hiroo Seki, Hiroyuki Sci Rep Article Massive obstetric haemorrhage remains a major cause of maternal death attributable to hypofibrinogenaemia. Transfusion of large volumes of fresh frozen plasma (FFP) is required to normalise fibrinogen levels. We compared the efficacy of FFP (F group) with that of FFP plus fibrinogen concentrate (F + F group) in massive obstetric haemorrhage. In this retrospective study, we compared the medical charts (2004–2016) of 137 patients with <150 mg/dl fibrinogen treated with F + F (n = 47; after August 2009) or F (n = 56; before August 2009). Although fibrinogen concentrate was only administered in severe cases, the FFP/red blood cell concentrate (RCC) ratio was significantly lower in the F + F group than in the F group. A sub-group analysis of cases requiring ≥18 RCC units showed that the F + F group received significantly less FFP than the F group (40.2 ± 19.6 versus 53.4 ± 18.5 units; P = 0.047) and showed significantly less pulmonary oedema (24.0% vs 57.1%; P < 0.05) in the absence of any significant differences in pre-transfusion coagulation, estimated blood loss, or RCC transfusion volume. Administration of fibrinogen concentrate increased the rate of fibrinogen supplementation five-fold and reduced FFP dosage, the FFP/RCC ratio, and the incidence of pulmonary oedema. Nature Publishing Group 2017-04-24 /pmc/articles/PMC5402272/ /pubmed/28436465 http://dx.doi.org/10.1038/srep46749 Text en Copyright © 2017, The Author(s) http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
spellingShingle Article
Matsunaga, Shigetaka
Takai, Yasushi
Nakamura, Eishin
Era, Sumiko
Ono, Yoshihisa
Yamamoto, Koji
Maeda, Hiroo
Seki, Hiroyuki
The Clinical Efficacy of Fibrinogen Concentrate in Massive Obstetric Haemorrhage with Hypofibrinogenaemia
title The Clinical Efficacy of Fibrinogen Concentrate in Massive Obstetric Haemorrhage with Hypofibrinogenaemia
title_full The Clinical Efficacy of Fibrinogen Concentrate in Massive Obstetric Haemorrhage with Hypofibrinogenaemia
title_fullStr The Clinical Efficacy of Fibrinogen Concentrate in Massive Obstetric Haemorrhage with Hypofibrinogenaemia
title_full_unstemmed The Clinical Efficacy of Fibrinogen Concentrate in Massive Obstetric Haemorrhage with Hypofibrinogenaemia
title_short The Clinical Efficacy of Fibrinogen Concentrate in Massive Obstetric Haemorrhage with Hypofibrinogenaemia
title_sort clinical efficacy of fibrinogen concentrate in massive obstetric haemorrhage with hypofibrinogenaemia
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5402272/
https://www.ncbi.nlm.nih.gov/pubmed/28436465
http://dx.doi.org/10.1038/srep46749
work_keys_str_mv AT matsunagashigetaka theclinicalefficacyoffibrinogenconcentrateinmassiveobstetrichaemorrhagewithhypofibrinogenaemia
AT takaiyasushi theclinicalefficacyoffibrinogenconcentrateinmassiveobstetrichaemorrhagewithhypofibrinogenaemia
AT nakamuraeishin theclinicalefficacyoffibrinogenconcentrateinmassiveobstetrichaemorrhagewithhypofibrinogenaemia
AT erasumiko theclinicalefficacyoffibrinogenconcentrateinmassiveobstetrichaemorrhagewithhypofibrinogenaemia
AT onoyoshihisa theclinicalefficacyoffibrinogenconcentrateinmassiveobstetrichaemorrhagewithhypofibrinogenaemia
AT yamamotokoji theclinicalefficacyoffibrinogenconcentrateinmassiveobstetrichaemorrhagewithhypofibrinogenaemia
AT maedahiroo theclinicalefficacyoffibrinogenconcentrateinmassiveobstetrichaemorrhagewithhypofibrinogenaemia
AT sekihiroyuki theclinicalefficacyoffibrinogenconcentrateinmassiveobstetrichaemorrhagewithhypofibrinogenaemia
AT matsunagashigetaka clinicalefficacyoffibrinogenconcentrateinmassiveobstetrichaemorrhagewithhypofibrinogenaemia
AT takaiyasushi clinicalefficacyoffibrinogenconcentrateinmassiveobstetrichaemorrhagewithhypofibrinogenaemia
AT nakamuraeishin clinicalefficacyoffibrinogenconcentrateinmassiveobstetrichaemorrhagewithhypofibrinogenaemia
AT erasumiko clinicalefficacyoffibrinogenconcentrateinmassiveobstetrichaemorrhagewithhypofibrinogenaemia
AT onoyoshihisa clinicalefficacyoffibrinogenconcentrateinmassiveobstetrichaemorrhagewithhypofibrinogenaemia
AT yamamotokoji clinicalefficacyoffibrinogenconcentrateinmassiveobstetrichaemorrhagewithhypofibrinogenaemia
AT maedahiroo clinicalefficacyoffibrinogenconcentrateinmassiveobstetrichaemorrhagewithhypofibrinogenaemia
AT sekihiroyuki clinicalefficacyoffibrinogenconcentrateinmassiveobstetrichaemorrhagewithhypofibrinogenaemia